Abstract
We performed in vitro and in vivo experiments to evaluate the pharmacological profile of ritobegron and its effects on the bladder in rats. β(3)-AR selectivity was assessed using CHO cells expressing various subtypes of the human β-adrenoceptor (AR). Effects on isolated organs were evaluated using the organ-bath method. Effects on intravesical pressure, heart rate, and mean blood pressure were evaluated in urethane-anesthetized rats. Ritobegron increased cAMP accumulation in a concentration-dependent manner in CHO cells expressing any one of three human β-AR, its selectivity for β(3)-AR being 301-fold and 32-fold higher versus β(1)-AR and β(2)-AR, respectively. Ritobegron decreased the resting tension of the isolated bladder in a concentration-dependent manner (EC(50), 7.7 × 10(-8) mol/L; maximal relaxation, 97.0 %), and the β(3)-AR antagonist SR58894A produced a parallel rightward-shift of this concentration-response curve without altering the maximal response [pK(B) value, 6.43]. Ritobegron concentration-dependently increased atrial rate and decreased myometrial contractions in vitro, and its selectivity for the bladder was 2,078-fold higher versus the atria and 14-fold higher versus the uterus. In vivo, ritobegron induced a ...Continue Reading
References
May 1, 1989·Journal of Molecular and Cellular Cardiology·C R JonesR J Summers
Oct 1, 1987·Biology of Reproduction·C LegrandY Benghan-Eyene
Jul 1, 1998·British Journal of Pharmacology·Y YamazakiY Ajisawa
Oct 20, 1998·Acta Physiologica Scandinavica·Y IgawaO Nishizawa
Mar 19, 1999·Experimental Physiology·K E Andersson
Apr 3, 1999·British Journal of Pharmacology·Y IgawaK E Andersson
Dec 23, 2000·The Journal of Urology·Y IgawaK E Andersson
Mar 16, 2001·The Tohoku Journal of Experimental Medicine·T YanagisawaK Nunoki
Aug 8, 2001·The Journal of Urology·M WoodsT M Argentieri
Feb 22, 2002·Japanese Journal of Pharmacology·Hiroo TakedaOsamu Nishizawa
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
May 15, 2002·Urology·Osamu Yamaguchi
Oct 17, 2002·Neurourology and Urodynamics·Hiroo TakedaKarl-Erik Andersson
Jul 11, 2003·The Journal of Urology·Masanori Nomiya, Osamu Yamaguchi
Citations
May 31, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Yasuhiko IgawaMartin C Michel
Dec 25, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Yasuhiko Igawa, Martin C Michel
Nov 12, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Martin C Michel
Aug 22, 2015·Expert Opinion on Investigational Drugs·Ganesh ThiagamoorthyLinda Cardozo
Sep 12, 2015·Expert Opinion on Emerging Drugs·Roopali Karmarkar, Vik Khullar
Oct 16, 2013·Neurourology and Urodynamics·Christopher R ChappleMartin C Michel
Oct 1, 2015·European Urology·Gian Marco RosaChristopher R Chapple
Feb 2, 2016·Current Medical Research and Opinion·Adrian WaggTodd Berner
May 11, 2016·Clinical Pharmacology in Drug Development·Yoshikazu AbeMamoru Kobayashi
Jul 1, 2015·Journal of Medicinal Chemistry·Yasuhiro WadaSatoshi Shuto
Nov 8, 2014·International Urogynecology Journal·Emilio Sacco, Riccardo Bientinesi
Jun 3, 2016·Expert Opinion on Pharmacotherapy·Ganesh ThiagamoorthyDudley Robinson
Oct 1, 2013·Urology·Sayoko KanieHidenori Mochizuki
Mar 30, 2017·Journal of Medicinal Chemistry·Yasuhiro WadaSatoshi Shuto
Sep 2, 2015·Drugs·Ilias GiarenisLinda Cardozo
Jan 1, 2012·Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi·Itaru MaruyamaHiroshi Kusama
Mar 15, 2019·British Journal of Pharmacology·Yasuhiko IgawaMartin C Michel
Mar 7, 2021·European Journal of Pharmacology·Naoki AizawaTomoe Fujita